Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis

Yuki Tahata; Ryotaro Sakamori; Kazuki Maesaka; Akira Doi; Ryoko Yamada; Takahiro Kodama; Hayato Hikita; Masanori Miyazaki; Yasutoshi Nozaki; Akira Kaneko; Masahide Oshita; Satoshi Tanaka; Kazuho Imanaka; Naoki Hiramatsu; Naoki Morishita; Kazuyoshi Ohkawa; Takayuki Yakushijin; Mitsuru Sakakibara; Sadaharu Iio; Yoshinori Doi; Tomohide Tatsumi; Tetsuo Takehara

doi:10.1111/hepr.13868

Abstract

This is the authors' abstract. We don't add key points for this paper.

SOF/VEL therapy may suppress the development of decompensated events and improve the prognosis in decompensated cirrhotic patients; however, the incidence of HCC remains prevalent in these patients irrespective of SOF/VEL therapy.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tahata et al. (2022) studied this question.

synapsesocial.com/papers/69da245d00ab073a27837e94 https://doi.org/10.1111/hepr.13868

View at Publisher

Ask AI

Bookmark

Share

Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis

Abstract

Ask about this paper

Discussion

Cite This Study

Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading